Cord blood infusion now available for long COVID patients under expanded access

NCT ID NCT07332338

AVAILABLE Disease control Sponsor: StemCyte, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers REGENECYTE, a human umbilical cord blood infusion, to adults with Long COVID who cannot join other clinical trials. Participants must have a recent negative COVID-19 test and provide consent. The goal is to provide potential treatment access while gathering safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human umbilical cord blood (REGENECYTE) infusion
What this could lead to: If it works, this could provide a treatment option for people with Long COVID who have no other trial options.
What could go wrong: This is an expanded access program, not a controlled trial, so results are uncertain. Risks of infusion include allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC FATIGUE CHRONIC FATIGUE SYMPTOMS FATIGUE POST VIRAL LONG COVID POST COVID CONDITION POST COVID-19 CONDITION POST-COVID SYNDROME

Contacts and locations

Locations

D&H National Research Center #1
AVAILABLE

Miami, Florida, 33169, United States
Myrak Research Center Inc.
AVAILABLE

Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.